nach oben

Erschienen in:

30.08.2022 | Original Article

Occurrence of malignant diseases in patients with multiple sclerosis: population-based MS Registry data

verfasst von: Gorica Maric, Tatjana Pekmezovic, Sarlota Mesaros, Olivera Tamas, Nikola Veselinovic, Maja Budimkic Stefanovic, Aleksa Jovanovic, Jelena Drulovic

Erschienen in: Neurological Sciences | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Among different comorbidities occurring in multiple sclerosis (MS), the presence of malignant diseases in these patients is of the particular importance. The aim of this study was to determine the malignant diseases burden in a whole cohort of patients with MS in the Belgrade region, based on the Belgrade population registry data.

Material and methods

This study comprises 2725 MS patients from the MS Registry, which represents a source for all necessary demographic and clinical data. Firstly, the Registry was searched for all persons with MS who had cancer comorbidity, during the period 1996–2019. Diagnosis of cancer was validated by the patients’ medical documentation. In order to investigate factors associated with the occurrence of any type of the cancer and/ or breast cancer only, in persons with MS, different logistic regression analyses were performed.

Results

A total of 64 persons with 69 malignant diseases were observed (prevalence 2.53%). The most frequent malignancies in males were skin cancer (50.0%) and in females, breast cancer (23.2%). The cumulative incidence of cancer comorbidity in persons with MS was 324.9 new cases per 100,000 person-years for the total population (137.6/100,000 in males and 403.6 per 100,000 in females). Comparison of cancer incidence rate between MS and general Belgrade population revealed lower risk for malignancy occurrence in the MS population in total (standardized incidence ratio, SIR = 0.58, 95% CI 0.16–1.49).

Conclusions

Our findings demonstrate that MS patients in the Belgrade region have lower risk for the development of malignancy than age- and sex-matched general population.

Coetzee T, Thompson AJ (2020) Atlas of MS 2020: Informing global policy change. Mult Scler 26:1807–1808. https://doi.org/10.1177/1352458520968811CrossRefPubMed

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G (2019) International consensus on quality standards for brain health-focused care in multiple sclerosis. Mult Scler 25:1809–1818. https://doi.org/10.1177/1352458518809326CrossRefPubMed

Marrie RA, Maxwell C, Mahar A, Ekuma O, McClintock C, Seitz D, Webber C, Groome PA (2021) Cancer incidence and mortality rates in multiple sclerosis: a matched cohort study. Neurology 96:e50–e512. https://doi.org/10.1212/WNL.0000000000011219CrossRef

Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Leung S, Yu N (2015) Effect of comorbidity on mortality in multiple sclerosis. Neurology 85:240–247. https://doi.org/10.1212/WNL.0000000000001718CrossRefPubMedPubMedCentral

Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M (2009) Defining comorbidity: implications for understanding health and health services. Ann Fam Med 7:357–363. https://doi.org/10.1370/afm.983CrossRefPubMedPubMedCentral

Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N (2015) A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler 21:263–281. https://doi.org/10.1177/1352458514564491CrossRefPubMedPubMedCentral

Moisset X, Perié M, Pereira B, Dumont E, Lebrun-Frenay C, Lesage FX, Dutheil F, Taithe F, Clavelou P (2017) Decreased prevalence of cancer in patients with multiple sclerosis: a case-control study. PLoS ONE 12:e0188120. https://doi.org/10.1371/journal.pone.0188120CrossRefPubMedPubMedCentral

Lalmohamed A, Bazelier M, Van Staa T, Uitdehaag BM, Leufkens HG, De Boer A, De Vries F (2012) Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 19:1007–1014. https://doi.org/10.1111/j.1468-1331.2012.03668.xCrossRefPubMed

Jick S, Li L, Falcone G, Vassilev Z, Wallander M-A (2014) Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol 261:1508–1517. https://doi.org/10.1007/s00415-014-7370-3CrossRefPubMedPubMedCentral

10.

Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T (2009) Cancer risk among patients with multiple sclerosis and their parents. Neurology 72:1170–1177. https://doi.org/10.1212/01.wnl.0000345366.10455.62CrossRefPubMed

11.

Ghajarzadeh M, Mohammadi A, Sahraian MA (2020) Risk of cancer in multiple sclerosis (MS): a systematic review and meta-analysis. Autoimmun Rev 19:102650. https://doi.org/10.1016/j.autrev.2020.102650CrossRefPubMed

12.

Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H (2014) Assessment of cancer risk with β-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry 85:1096–1102. https://doi.org/10.1136/jnnp-2013-307238CrossRefPubMed

13.

Ragonese P, Aridon P, Vazzoler G, Mazzola MA, Lo Re V, Lo Re M, Realmuto S, Alessi S, D’Amelio M, Savettieri G, Salemi G (2017) Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurol 17:155. https://doi.org/10.1186/s12883-017-0932-0CrossRefPubMedPubMedCentral

14.

Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, Debouverie M, de Seze J, Wiertlevsky S, Heinzlef O, Tourbah A, Fromont A, Frenay M (2011) Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol 258:1304–1311. https://doi.org/10.1007/s00415-011-5929-9CrossRefPubMed

15.

Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S (2015) All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: a Swedish population-based cohort study. Eur J Neurol 22:1074–1080. https://doi.org/10.1111/ene.12710CrossRefPubMed

16.

Melamed E, Lee MW (2020) Multiple sclerosis and cancer: the Ying-Yang effect of disease modifying therapies. Front Immunol 10:2954. https://doi.org/10.3389/fimmu.2019.02954CrossRefPubMedPubMedCentral

17.

Maric GD, Pekmezovic TD, Mesaros ST, Tamas OS, Ivanovic JB, Martinovic VN, Andabaka MM, Jovanovic AL, Veselinovic ND, Kisic-Tepavcevic DB, Drulovic JS (2021) The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data. Neurol Sci 42:1887–1893. https://doi.org/10.1007/s10072-020-04727-5CrossRefPubMed

18.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452. https://doi.org/10.1212/wnl.33.11.1444CrossRefPubMed

19.

Serbian cancer registry. Malignant tumors in the Republic of Serbia (2019) Institute of Public Health of Serbia “Dr Milan Jovanović Batut”, 2021. Available at: https://www.batut.org.rs/download/publikacije/maligniTumoriURepubliciSrbiji2019.pdf

20.

Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H (2012) Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 135:2973–2979. https://doi.org/10.1093/brain/aws148CrossRefPubMed

21.

Nosek MA, Howland CA (1997) Breast and cervical cancer screening among women with physical disabilities. Arch Phys Med Rehabil 78(12 Suppl 5):S39–44. https://doi.org/10.1016/s0003-9993(97)90220-3CrossRefPubMed

22.

Norgaard M, Veres K, Didden EM, Wormser D, Magyari M (2019) Multiple sclerosis and cancer incidence: a Danish nationwide cohort study. Mult Scler Relat Disordx 28:81–85. https://doi.org/10.1016/j.msard.2018.12.014CrossRef

23.

Capkun G, Dahlke F, Lahoz R, Nordstrom B, Tilson HH, Cutter G, Bischof D, Moore A, Simeone J, Fraeman K, Bancken F, Geissbühler Y, Wagner M, Cohan S (2015) Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord 4:546–554. https://doi.org/10.1016/j.msard.2015.08.005CrossRefPubMed

24.

Grytten N, Myhr KM, Celius EG, Benjaminsen E, Kampman MT, Midgard R, Vatne A, Aarseth JH, Riise T, Torkildsen Ø (2021) Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study. Mult Scler Relat Disord 55:103209. https://doi.org/10.1016/j.msard.2021.103209CrossRefPubMed

25.

Benjaminsen E, Myhr KM, Grytten N, Alstadhaug KB (2021) Comorbidity in multiple sclerosis patients from Nordland County, Norway - validated data from the Norwegian Patient Registry. Mult Scler Relat Disord 48:102691. https://doi.org/10.1016/j.msard.2020.102691CrossRefPubMed

26.

Sun LM, Lin CL, Chung CJ, Liang JA, Sung FC, Kao CH (2014) Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study. Eur J Neurol 21:238–244. https://doi.org/10.1111/ene.12267CrossRefPubMed

27.

White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ (2014) Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 46(3 Suppl 1):S7–15. https://doi.org/10.1016/j.amepre.2013.10.029CrossRefPubMedPubMedCentral

28.

Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, Weinstock-Guttman B (2019) Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 15:329–342. https://doi.org/10.1038/s41582-019-0183-3CrossRefPubMed

29.

Mesaros S, Stojsavljevic N, Dujmovic I, Mandic E, Drulovic J (2004) Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis. Srp Arh Celok Lek 132:209–213. https://doi.org/10.2298/sarh0408209mCrossRefPubMed

30.

Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW (2010) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74:1463–70. https://doi.org/10.1212/WNL.0b013e3181dc1ae0CrossRefPubMedPubMedCentral

31.

Colovic N, Suvajdzic N, Kraguljac Kurtovic N, Djordjevic V, Dencic Fekete M, Drulovic J, Vidovic A, Tomin D (2012) Therapy-related acute leukemia in two patients with multiple sclerosis treated with mitoxantrone. Biomed Pharmacother 66:173–174. https://doi.org/10.1016/j.biopha.2011.10.004CrossRefPubMed

32.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90:777–788. https://doi.org/10.1212/WNL.0000000000005347CrossRefPubMed

Titel: Occurrence of malignant diseases in patients with multiple sclerosis: population-based MS Registry data
verfasst von: Gorica Maric
Tatjana Pekmezovic
Sarlota Mesaros
Olivera Tamas
Nikola Veselinovic
Maja Budimkic Stefanovic
Aleksa Jovanovic
Jelena Drulovic
Publikationsdatum: 30.08.2022
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 12/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06362-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Material and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Pre-operative cognitive burden as predictor of motor outcome following bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease

Sensory-motor not length-dependent multineuropathy followed by the syringomyelia-like phenotype: a novel presentation of Tangier disease

Correction to: Long‑term outcomes of ruptured saccular intracranial aneurysm clipping versus coiling: systematic review and eta‑analysis of randomized controlled trials

Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience

Seizures in a patient with Guillain Barre syndrome: are antibodies disrupting the blood brain barrier?

Reply to Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”